Abstract
Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1480-1484 |
| Number of pages | 5 |
| Journal | Clinical Infectious Diseases |
| Volume | 54 |
| Issue number | 10 |
| DOIs | |
| State | Published - May 15 2012 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Cite this
Miconazole mucoadhesive tablets : A novel delivery system. / Vazquez, Jose Antonio; Sobel, Jack D.
In: Clinical Infectious Diseases, Vol. 54, No. 10, 15.05.2012, p. 1480-1484.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Miconazole mucoadhesive tablets
T2 - A novel delivery system
AU - Vazquez, Jose Antonio
AU - Sobel, Jack D.
PY - 2012/5/15
Y1 - 2012/5/15
N2 - Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.
AB - Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.
UR - http://www.scopus.com/inward/record.url?scp=84860251686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860251686&partnerID=8YFLogxK
U2 - 10.1093/cid/cis205
DO - 10.1093/cid/cis205
M3 - Review article
VL - 54
SP - 1480
EP - 1484
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 10
ER -